Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal Cord Injury Treatment
China’s National Medical Products Administration (NMPA) has approved the world’s first invasive brain-computer interface medical device for market entry. Developed by Borui Kang Medical Technology (Shanghai) Co., Ltd., this implantable system—named the Hand Movement Function Compensation System—targets patients with tetraplegia from C2-C6 cervical spinal cord injuries. It enables compensatory hand grasping via a pneumatic glove, with clinical trials showing significant improvements in hand function and marking a leap in neurotechnology.
Restoring Grip in Tetraplegia Patients
The device’s innovation restores hand grasping for those with severe limitations, backed by clinical gains. It includes an implantable invasive brain-computer interface unit, epidural electrocorticography electrode kit, wireless signal transceiver, pneumatic glove, disposable surgical tools, and decoding software. Using minimally invasive epidural implantation and wireless power, trials showed major hand function boosts for stable, refractory tetraplegia patients (ASIA Impairment Scale A-C). It’s for adults 18-60 with conditions stable over six months post one-year diagnosis, retaining some upper arm function—positioning this invasive brain-computer interface as a global first.
Fast-Track Review Under Five-Year Plan
NMPA’s approval follows China’s “15th Five-Year Plan” strategy, with an “early intervention, one-product-one-strategy, full guidance, integrated research-review” model. This featured prioritized resources, pre-submission support, and interdepartmental coordination to speed reviews, supporting medical-engineering integration and innovation without safety trade-offs.
Reshaping Economics of Neurorehab Devices
This milestone potentially transforming market access, pricing, and reimbursement for invasive brain-computer interface technologies in spinal cord care. Real-world quality-of-life evidence from functional gains could support pricing decisions integrated in Health Technology Assessments (HTA) submissions in global markets. With NMPA’s accelerated approvals for neural innovations, it may spur regulatory efficiencies worldwide, balancing implantation costs against long-term caregiving savings, with post-market surveillance ensuring payer trust and broader access.
